Immunotherapy with Anti-PD-1 Effective for Patients with Solid Tumors

A review of 13 clinical trials published in JAMA Oncology found that patients with solid tumors, including stomach tumors, had better survival outcomes when they took anti-PD-1 drugs, as compared to patients prescribed anti-PD-L1 medicines.